Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma

Brentuximab vedotin is an antibody–drug conjugate that selectively delivers the antimicrotubule agent monomethyl auristatin E into CD30-expressing cells. To assess its safety, pharmacokinetics, and efficacy in Japanese patients with refractory or relapsed CD30-positive Hodgkin's lymphoma or sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Ishizawa, Kenichi, Uike, Naokuni, Uchida, Toshiki, Suzuki, Tatsuya, Aoki, Tomohiro, Watanabe, Takashi, Maruyama, Dai, Yokoyama, Masahiro, Takubo, Takatoshi, Kagehara, Hideaki, Matsushima, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317919/
https://www.ncbi.nlm.nih.gov/pubmed/24814862
http://dx.doi.org/10.1111/cas.12435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317919/
https://www.ncbi.nlm.nih.gov/pubmed/24814862
http://dx.doi.org/10.1111/cas.12435

Ejemplares similares